BIT:1GILD - Euronext Milan - US3755581036 - Common Stock - Currency: EUR
BIT:1GILD (5/12/2025, 7:00:00 PM)
92.49
+5.43 (+6.24%)
The current stock price of 1GILD.MI is 92.49 EUR. In the past month the price increased by 6.31%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 17.73 | 284.81B | ||
AMG.DE | AMGEN INC | 12.92 | 127.52B | ||
GIS.DE | GILEAD SCIENCES INC | 13.72 | 116.82B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 98.00B | ||
ARGX.BR | ARGENX SE | 108.79 | 31.42B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 20.63B | ||
IDP.DE | BIOGEN INC | 7.94 | 16.29B | ||
1BIIB.MI | BIOGEN INC | 7.52 | 16.03B | ||
1MRNA.MI | MODERNA INC | N/A | 8.92B | ||
0QF.DE | MODERNA INC | N/A | 8.78B | ||
BIO.DE | BIOTEST AG | 65.54 | 1.69B | ||
GLPG.AS | GALAPAGOS NV | N/A | 1.68B |
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The firm is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. The company is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. The company operates in more than 35 countries worldwide.
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 17600
Phone: 16505743000
The current stock price of 1GILD.MI is 92.49 EUR. The price increased by 6.24% in the last trading session.
The exchange symbol of GILEAD SCIENCES INC is 1GILD and it is listed on the Euronext Milan exchange.
1GILD.MI stock is listed on the Euronext Milan exchange.
36 analysts have analysed 1GILD.MI and the average price target is 103.59 EUR. This implies a price increase of 12% is expected in the next year compared to the current price of 92.49. Check the GILEAD SCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
GILEAD SCIENCES INC (1GILD.MI) has a market capitalization of 115.15B EUR. This makes 1GILD.MI a Large Cap stock.
GILEAD SCIENCES INC (1GILD.MI) currently has 17600 employees.
GILEAD SCIENCES INC (1GILD.MI) has a support level at 87.06. Check the full technical report for a detailed analysis of 1GILD.MI support and resistance levels.
The Revenue of GILEAD SCIENCES INC (1GILD.MI) is expected to grow by 1.08% in the next year. Check the estimates tab for more information on the 1GILD.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
GILEAD SCIENCES INC (1GILD.MI) has a dividend yield of 3.15%. The yearly dividend amount is currently 2.81. Check the full fundamental report for a detailed analysis of 1GILD.MI dividend history, reliability and sustainability.
GILEAD SCIENCES INC (1GILD.MI) will report earnings on 2025-08-06, after the market close.
The PE ratio for GILEAD SCIENCES INC (1GILD.MI) is 13.52. This is based on the reported non-GAAP earnings per share of 6.84 and the current share price of 92.49 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1GILD.MI.
ChartMill assigns a technical rating of 4 / 10 to 1GILD.MI.
ChartMill assigns a fundamental rating of 7 / 10 to 1GILD.MI. 1GILD.MI has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Over the last trailing twelve months 1GILD.MI reported a non-GAAP Earnings per Share(EPS) of 6.84. The EPS increased by 77.93% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 20.76% | ||
ROA | 10.57% | ||
ROE | 31.13% | ||
Debt/Equity | 1.16 |
ChartMill assigns a Buy % Consensus number of 80% to 1GILD.MI. The Buy consensus is the average rating of analysts ratings from 36 analysts.
For the next year, analysts expect an EPS growth of 76.07% and a revenue growth 1.08% for 1GILD.MI